Af­ter the ap­plause: New ef­fi­ca­cy ex­pec­ta­tions in urothe­lial can­cer af­ter Pad­cev-Keytru­da da­ta re­veal

Urothe­lial can­cer on­col­o­gist Matthew Gal­sky has trou­ble re­mem­ber­ing the last time there was a stand­ing ova­tion for clin­i­cal tri­al da­ta at a med­ical con­fer­ence. But he wasn’t sur­prised that con­fir­ma­to­ry da­ta from a Phase III tri­al study­ing Seagen and Astel­las’ Pad­cev plus Mer­ck’s Keytru­da in first-line blad­der can­cer was met with one just over a week ago at ES­MO.

“Since the de­vel­op­ment of plat­inum-based chemother­a­py around 30-plus years ago, there have been no im­prove­ments in sur­vival in pa­tients with metasta­t­ic blad­der can­cer or urothe­lial can­cer,” said Gal­sky, a pro­fes­sor at the Ic­ahn School of Med­i­cine at Mount Sinai.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER